Ozempic and Weight Loss: What the Research Shows

Since 2023, GLP-1 receptor agonists — particularly semaglutide (sold as Ozempic and Wegovy) — have become the most talked-about development in weight management medicine. Clinical trials have produced results that were previously unachievable without surgery. Here's what the evidence actually shows.

What Is Ozempic? How Do GLP-1 Medications Work?

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It:

• Signals the pancreas to release insulin in response to blood glucose
• Slows gastric emptying (food moves more slowly from the stomach to the small intestine)
• Acts on appetite centres in the brain to reduce hunger and food cravings
• Increases feelings of fullness after meals

GLP-1 medications mimic and amplify this natural hormone, producing sustained appetite reduction and slower digestion that leads to lower calorie intake without deliberate effort. This is distinct from willpower-based dieting — the medication physiologically reduces hunger signals.

Ozempic vs Wegovy vs Mounjaro: What's the Difference?

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist that produces the largest weight loss seen in any drug trial to date — an average of 20–22% of body weight at the highest dose in the SURMOUNT-1 trial.

Clinical Trial Results: How Much Weight Do People Actually Lose?

Wegovy (semaglutide 2.4mg) — STEP 1 Trial

The landmark STEP 1 trial (2021, published in NEJM) enrolled 1,961 adults with BMI ≥30 (or ≥27 with weight-related comorbidities). After 68 weeks:

• Average weight loss: 14.9% of body weight (vs 2.4% in the placebo group)
• 86% of participants achieved ≥5% weight loss
• 69% achieved ≥10% weight loss
• 50% achieved ≥15% weight loss

For a 100 kg person, 14.9% = approximately 15 kg lost over 16 months.

Mounjaro (tirzepatide 15mg) — SURMOUNT-1 Trial

The SURMOUNT-1 trial (2022, NEJM) enrolled 2,539 adults without diabetes. At the highest dose (15mg weekly) after 72 weeks:

• Average weight loss: 22.5% of body weight
• 96% achieved ≥5% weight loss
• 57% achieved ≥20% weight loss

These results approach what has historically only been achievable through bariatric surgery.

What Happens When You Stop Taking GLP-1 Medications?

This is the most important caveat. A 2022 trial published in Diabetes, Obesity and Metabolism followed participants for one year after stopping Wegovy. The findings:

• Participants regained an average of two-thirds of their lost weight within 12 months of stopping
• Most metabolic improvements (blood pressure, blood glucose, lipids) also reversed

This reflects current understanding of obesity as a chronic condition requiring ongoing treatment — similar to how antihypertensives require continued use to maintain blood pressure control. The medications suppress, rather than cure, the physiological drivers of excess weight.

Side Effects

The most common side effects from GLP-1 clinical trials:

Serious but rare side effects include pancreatitis and gallbladder disease. GLP-1 medications carry a black box warning for medullary thyroid carcinoma in rodent studies (clinical significance in humans is uncertain, but people with personal or family history of this cancer should not use these medications).

Who Qualifies for GLP-1 Weight Loss Medications?

Eligibility criteria in most countries (NHS, FDA) for Wegovy/Mounjaro prescribed for weight management:

• BMI ≥30 (obese), OR
• BMI ≥27 with at least one weight-related health condition (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease)
• No personal or family history of medullary thyroid carcinoma or MEN2
• No history of pancreatitis
• Previous attempts at diet and lifestyle modification

Use our BMI Calculator to find your current BMI and see if you meet the threshold. Discuss with your GP or an obesity medicine specialist.

GLP-1 Medications and Muscle Loss

An important consideration often overlooked: approximately 40% of weight lost on GLP-1 medications is lean mass (muscle), not just fat. This is similar to what happens with rapid calorie restriction without exercise.

To mitigate muscle loss while on GLP-1 medications:

• Maintain high protein intake (1.2–1.6 g/kg body weight) — use our Protein Calculator
• Engage in resistance training at least 2–3 times per week
• Avoid excessively aggressive calorie restriction on top of the appetite suppression